Therapy of autoimmune diseases by novel immunosuppressant FTY720

Sachi Tsunemi; Tsuyoshi Iwasaki; Keiji Miyazawa; Sachie Kitano; Chieri Kanda; Harunori Takeshita; Masahiro Sekiguchi; Masayasu Kitano; Hajime Sano

doi:10.2492/inflammregen.31.307

Mini Review

Therapy of autoimmune diseases by novel immunosuppressant FTY720

Sachi Tsunemi, Tsuyoshi Iwasaki, Keiji Miyazawa, Sachie Kitano, Chieri Kanda, Harunori Takeshita, Masahiro Sekiguchi, Masayasu Kitano, Hajime Sano

著者情報

Sachi Tsunemi
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine
Tsuyoshi Iwasaki
Division of Pharmacotherapy, Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences
Keiji Miyazawa
R&D Planning, Kissei Pharmaceutical Co Ltd
Sachie Kitano
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine
Chieri Kanda
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine
Harunori Takeshita
Division of Pharmacotherapy, Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences
Masahiro Sekiguchi
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine
Masayasu Kitano
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine
Hajime Sano
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine

キーワード: FTY720, sphingosine 1-phosphate, rheumatoid arthritis, SKG mouse, autoimmunity

ジャーナルフリー

2011 年 31 巻 3 号 p. 307-315

DOI https://doi.org/10.2492/inflammregen.31.307

詳細

抄録

FTY720 (FTY) is a new immunosuppressant which modulates sphingosine 1-phospate receptors. FTY has been shown to be highly effective to multiple sclerosis in clinical studies. Recently, we reported the effects and the mechanisms by which FTY inhibited arthritis in rheumatoid arthritis model of SKG mice. Here, we briefly review up to date reports of FTY including our experimental results.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）